Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol - - FDA agreed that a single pivotal Phase 3 trial ...

Five-agent AI team could speed clinical trial design using real-world patient records

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial ...
Business Insider

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I ...

Alterity kicks FDA goal as US regulator backs Phase III pathway for ATH434 in MSA

Official minutes from Alterity Therapeutics’ End-of-Phase II meeting with the US Food and Drug Administration, confirm a ...

Alterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathway

Alterity Therapeutics Ltd (ASX:ATH) has received official US Food and Drug Administration meeting minutes confirming a ...

Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

CurePSP Expands Grant Program with $155,000 Investment in Studying Care for Rare Neurological Diseases

CurePSP announced the latest recipients of the Collaborative Approaches to Resources, Education and Support (CARES) grants, awarding a total of $155,000 to four projects spanning seven leading medical ...
Stockhead

Three ASX biotechs working to solve the neurodegenerative disease puzzle

Several ASX healthcare companies are tackling neurodegenerative diseases where effective treatments remain limited.

Experimental drug alleviates symptoms of Huntington's disease

The hereditary disorder Huntington's disease has so far been considered incurable. Its clinical manifestations include ...

Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.
Ophthalmology Times

Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...